Psilocybin mushrooms are not considered physically dangerous for most healthy adults in moderate doses. They carry a very low risk of fatal overdose, don’t cause physical dependence, and haven’t been linked to long-term cognitive decline. That said, they do carry real psychological risks, especially for people with a personal or family history of psychotic disorders, and the unregulated nature of recreational use introduces its own hazards.
Overdose Risk Is Extremely Low
No confirmed lethal dose of psilocybin has been established in humans. Animal studies put the lethal dose so high that a person would need to consume an almost inconceivable quantity of mushrooms to reach it. The one documented death attributed directly to psilocybin involved a massive dose that produced blood levels roughly 1,000 times higher than what a typical recreational dose creates. For practical purposes, a fatal overdose from eating psilocybin mushrooms alone is nearly unheard of.
That doesn’t mean the physical experience is entirely benign. At standard doses, people commonly report nausea, vomiting, muscle weakness, and visual disturbances. These effects are temporary and resolve as the drug wears off, typically within four to six hours.
What Happens to Your Heart and Blood Pressure
Psilocybin temporarily raises both heart rate and blood pressure in a dose-dependent way. Clinical trials have recorded blood pressure readings climbing to around 140/87 mmHg at moderate doses and as high as 155/90 mmHg at higher doses. Heart rates generally increase by about 5 to 15 beats per minute. In one study, 34% of participants given a high dose experienced a systolic blood pressure spike above 160 mmHg.
These changes are transient and haven’t required medical intervention in controlled settings. But if you have an existing heart condition or uncontrolled high blood pressure, even a temporary spike could be meaningful. Researchers have consistently described the cardiovascular effects as mild and self-resolving in healthy participants.
The Biggest Risk Is Psychological
The most common harm from psilocybin isn’t physical. It’s psychological. In a survey of 869 people who had used psychedelics, 64% reported experiencing some form of challenge during a trip, ranging from intense anxiety to full-blown panic. These “bad trips” can involve overwhelming fear, paranoia, confusion, and a distressing sense of losing control. For the vast majority of people, these feelings end when the drug wears off. But in rare cases, they can leave a lasting mark.
About 4.2% of psychedelic users develop a condition called Hallucinogen Persisting Perception Disorder, or HPPD. This involves re-experiencing visual disturbances from the trip long after the drug has left your system: things like trailing images, halos around objects, or visual snow. These are sometimes called pseudo-hallucinations because the person recognizes they aren’t real. For most people with HPPD, symptoms are mild. For a small number, they’re persistent and distressing.
Psychosis in Vulnerable Individuals
The most serious psychological risk applies to people who are already vulnerable to psychotic disorders. A review of published case reports found a clear pattern: psilocybin-induced psychosis occurs primarily in people with pre-existing risk factors. These include a personal or family history of schizophrenia, personality disorders (particularly schizoid or avoidant traits), depression, anxiety, and heavy cannabis use. Every documented case of psilocybin-triggered psychosis involved someone with at least one of these risk factors.
This is why clinical trials studying psilocybin as a treatment for depression routinely exclude anyone with a history of psychotic symptoms. It may be reassuring that low, controlled doses in screened individuals appear safe, but it also means we have very little data on what happens in the populations most likely to be harmed. If you have a family history of schizophrenia or bipolar disorder with psychotic features, the risk of triggering a psychotic episode is real and not well quantified.
Addiction Potential Is Very Low
Psilocybin is not considered addictive in the way that alcohol, nicotine, or opioids are. There are no known physical withdrawal symptoms. The Surgeon General’s report on addiction notes that it is not currently known whether psilocybin is addictive at all, and no medications exist to treat psilocybin dependence because dependence essentially isn’t a recognized clinical problem.
Tolerance builds rapidly with psilocybin. If you take it two days in a row, the second dose will produce significantly weaker effects. This built-in tolerance mechanism makes compulsive daily use self-limiting in a way that’s quite different from stimulants or opioids. Interestingly, psilocybin may actually reduce the perceived effects of alcohol when the two are combined.
No Evidence of Long-Term Cognitive Damage
One of the most common fears about psychedelics is that they’ll “fry your brain.” The research doesn’t support this. A large international study comparing lifetime psychedelic users to non-users found that lifetime use was not associated with long-term cognitive decline. In fact, lifetime users performed slightly better on several cognitive tasks, though researchers noted this likely reflects pre-existing differences between the groups rather than a brain-boosting effect of the drug itself. The correlation between total amount of psychedelics consumed and cognitive performance showed no significant relationship in either direction.
Mixing With Medications
If you take antidepressants, particularly SSRIs or MAOIs, combining them with psilocybin introduces additional risk. Both SSRIs and psilocybin act on the serotonin system, raising theoretical concerns about serotonin toxicity, a potentially dangerous condition where serotonin levels climb too high. The risk spectrum depends heavily on which medications are involved. Combining psilocybin with an MAOI carries the highest risk. Combining it with an SSRI alone (without an MAOI in the mix) is considered lower risk, but not zero.
Warning signs of serotonin toxicity include involuntary muscle jerks, extreme fluctuations in heart rate and blood pressure, agitation or unresponsiveness, muscle rigidity, high fever, and seizures. SSRIs also tend to blunt the subjective effects of psilocybin, which sometimes leads people to take higher doses to compensate, compounding the risk.
The Danger of Misidentified Mushrooms
One risk that has nothing to do with psilocybin itself is poisoning from the wrong mushroom. Several deadly species look similar enough to psilocybin-containing mushrooms that misidentification happens regularly. Species in the Amanita family, particularly the death cap (Amanita phalloides), contain toxins that cause liver failure, kidney failure, and death. Other lookalikes can cause seizures, severe gastrointestinal damage, or destruction of red blood cells. Cases of serious poisoning from misidentified wild mushrooms are reported every year. Foraging without expert-level knowledge is genuinely dangerous, and the consequences of getting it wrong are far more severe than anything psilocybin itself would cause.
Therapeutic Promise, With Caveats
Psilocybin has received FDA breakthrough therapy designations for both treatment-resistant depression and major depressive disorder, meaning the agency considers early evidence strong enough to fast-track its review. Two separate organizations, COMPASS Pathways and the Usona Institute, hold these designations. This is significant because breakthrough therapy status is reserved for treatments that may offer substantial improvement over existing options.
However, 2024 was widely considered a setback year for psychedelic medicine after the FDA rejected an application for MDMA-assisted therapy for PTSD, raising questions about the regulatory path for all psychedelic treatments. Psilocybin is not yet an approved medication anywhere in the U.S. federal system, and the therapeutic results seen in clinical trials come from carefully controlled environments with extensive screening, preparation, and professional support, conditions that are very different from recreational use.